Allergy Therapeutics

Helge Weiner‑Trapness will become executive chairman of Allergy Therapeutics, succeeding Peter Jensen OBE, who is stepping down as chair after more than 15 years. Weiner‑Trapness has served since January 2026 as chief strategy officer and executive director and brings over 30 years of investment banking experience, most recently as vice chairman, global banking at HSBC. He will share strategic leadership with CEO Manuel Llobet while the company examines a possible dual listing in Hong Kong. Jensen will remain as a non-executive director until the transition and will not stand for re-election at the next annual general meeting. » Więcej na de.investing.com

Allergy Therapeutics presented data from 15 presentations at the EAACI congress, including results from the Phase I/IIa PROTECT study of VLP Peanut, which met its primary endpoint and showed a favorable safety profile and a dose–response relationship. Blinded safety data from the first year of the Phase III G308 study of Grass MATA MPL in pediatric patients also showed a favorable safety profile and a low discontinuation rate. The company held a symposium on its programs and sponsored the EAACI Early Career Research Award. » Więcej na de.investing.com

Allergy Therapeutics reports clear biomarker-based efficacy signals with good tolerability from the Phase‑I/IIa PROTECT study of VLP Peanut. After three subcutaneous injections, up to a 2,000-fold increase in tolerated dose was observed without a relevant safety signal, reduced basophil sensitivity to peanut and Ara h2, and dose-dependent effects on Ara h2 binding and specific IgG (highest dose: p=0.003 for peanut, p=0.04 for Ara h2, p=0.0005 for IgG). One month after treatment, wheal diameter was reduced versus placebo. The analysis included four patients per dose group and seven placebo patients; the company plans a Phase‑IIb study and will evaluate long-term data up to one year. » Więcej na de.investing.com

Shareholders of Allergy Therapeutics approved at the general meeting the issuance of up to 610 million new common shares, about 10% of the current share capital. 99.98% voted in favor of the authorization to issue shares and 99.93% in favor of excluding pre-emptive rights, enabling private placements without an offer to existing shareholders. Proceeds from a potential issuance are intended to fund research into grass and peanut allergies, general corporate purposes and working capital ahead of a planned listing in Hong Kong. The company stresses that a capital raise is still uncertain and that no investor agreements or decisions on size or price have yet been made. » Więcej na de.investing.com

Allergy Therapeutics will seek authorization at the general meeting on 29 December 2025 to issue up to 610 million new ordinary shares, representing about 10% of the current share capital, and to exclude statutory subscription rights. The aim is to facilitate a possible capital increase ahead of the planned secondary listing in Hong Kong (first half of 2026) and to raise funds for the development of therapies for grass and peanut allergies as well as for general corporate purposes. There is no certainty that a capital increase will actually occur; neither the size nor the price have been determined, and no subscription agreements have been entered into so far. » Więcej na de.investing.com